摘要
随着各种肾脏替代疗法的广泛开展,尿毒症患者的寿命逐渐延长,肾性骨病已逐渐成为影响患者生活质量和生存时间的重要并发症之一,其治疗是目前临床上比较棘手的问题。降钙素(calcitonin)作为一种调节钙磷代谢的药物,其抑制骨吸收及镇痛的作用确切,用于原发性及继发性骨质疏松症治疗已得到广泛认同。但用于肾性骨病治疗国内少有报道,尚欠缺成熟的治疗经验。本文对降钙素的药学特征以及在治疗肾性骨病方面的临床应用现状及前景进行综述。
Renal osteodystrophy is tending to be one of primary complications in uremia,which commits malevolence to both the quality of life and longevity of patients.Although patients suffering with uremia have obtained more life span than before for extensive adoption of different renal substitution therapies.As yet,the renal osteodystrophy is diffi cult to be treated properly.Calcitonin is used for modulating the metabolism between the calcium and phosphorus.It has been consensus for calcitonin adminstered to trea...
出处
《世界临床药物》
CAS
2009年第2期87-89,共3页
World Clinical Drug
关键词
降钙素
肾性骨病
尿毒症
calcitonin
renal osteodystrophy
uremia
